To determine whether AZD5991 synergizes with FLT3 inhibition, FLT3-ITD positive AML cell lines MOLM-13 and MV4-11 were treated with the vehicle control, AZD5991, gilteritinib, or MRX-2843, alone or in combination, for 24 h. This evidence concerns the gene FLT3 and acute myeloid leukemia.